head JofIMAB
Journal of IMAB - Annual Proceeding (Scientific Papers)
Publisher: Peytchinski Publishing Ltd.
ISSN: 1312-773X (Online)
Issue: 2019, vol. 25, issue3
Subject Area: Medicine
DOI: 10.5272/jimab.2019253.2671
Published online: 27 August 2019

Original article

J of IMAB. 2019 Jul-Sep;25(3):2671-2674;
Tihomir Totev1ORCID logo Corresponding Autoremail, Desislava Kiprova2ORCID logo, Nadezhda Hinkova2ORCID logo,
1) Institute of Science and Research, Medical University - Pleven, Bulgaria.
2) St. Marina University Hospital, Medical University - Pleven, Bulgaria.

Purpose: To investigate the clinical and histopathological characteristics of patients with uterine and ovarian sarcomas and analyse surgical operations already performed.
Material and Methods: The retrospective study included 17 patients with uterine and 2 patients with ovarian sarcomas, who were diagnosed and operated on for three years at St. Marina University Hospital in Pleven, Bulgaria.
Results: In the group of uterine sarcomas, the highest incidence was that of leiomyosarcomas (53.3%), followed by endometrial stromal sarcomas (33.3%) and the homologous carcinosarcomas (13.3%). Most of the patients were diagnosed in the first clinical stage (73.3%), and the most common surgery performed was total abdominal hysterectomy with salpingo-oophorectomy, with or without omentectomy (53.3%). The two patients with ovarian tumours were histologically diagnosed with carcinosarcoma.
Genital sarcomas are a heterogeneous group of rare malignant diseases with poor prognoses. Early detection, adequate histological diagnosis and staging are of utmost importance for control.

Keywords: uterine sarcoma, ovarian sarcoma,

pdf - Download FULL TEXT /PDF 1472 KB/
Please cite this article as: Totev T, Kiprova D, Hinkova N. Uterine and ovarian sarcomas: clinical and histopathological characteristics. J of IMAB. 2019 Jul-Sep;25(3):2671-2674.
DOI: 10.5272/jimab.2019253.2671

Corresponding AutorCorrespondence to: Tihomir P. Totev MD, PhD, St. Marina University Hospital, Department of Gynecology; Bulgarska aviatsia str., Pleven 5800, Bulgaria; E-mail: t.totev@mail.bg

1. Shah SH, Jagannathan JP, Krajewski K, O'Regan KN, George S, Ramaiya NH. Uterine sarcomas: then and now. AJR Am J Roentgenol. 2012 Jul;199(1):213-23. [PubMed]
2. Kobayashi H, Uekuri C, Akasaka J, Ito F, Shigemitsu A, Koike N, et al. The biology of uterine sarcomas: A review and update. Mol Clin Oncol. 2013 Jul;1(4):599-609. [PubMed] [Crossref]
3. Spaziani E, Picchio M, Petrozza V, Briganti M, Ceci F, Di Filippo A. et al. Carcinosarcoma of the uterus: a case report and review of the literature. Eur J Gynaecol Oncol. 2008;29(5):531-4. [PubMed]
4. Benson C, Miah A. Uterine sarcoma – current perspectives. Int J Womens Health. 2017 Aug 31;9:597–606. [PubMed] [Crossref]
5. del Carmen MG, Birrer M, Schorge JO. Carcinosarcoma of the ovary: a review of the literature. Gynecol Oncol. 2012 Apr;125(1):271-7. [PubMed] [Crossref]
6. Harris MA, Delap LM, Sengupta PS, Wilkinson PM, Welch RS, Swindell R. et al. Carcinosarcoma of the ovary. Br J Cancer. 2003 Mar 10;88(5):654-7. [PubMed] [Crossref]
7. Makris GM, Siristatidis C, Battista MJ, Chrelias C. Ovarian carcinosarcoma: case report, diagnosis, treatment and literature review. Hippokratia. 2015 Jul-Sep;19(3):256-9. [PubMed]
8. Powell MA, Filiaci VL, Rose PG, Mannel RS, Hanjani P, Degeest K. et al. Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study. J Clin Oncol. 2010 Jun;28(16):2727-31. [PubMed] [Crossref]
9. Hensley ML, Blessing JA, Mannel, Rose PG. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. Gynecol Oncol. 2008 Jun;109(3):329-34. [PubMed] [Crossref].

Received: 14 February 2019
Published online: 27 August 2019

back to Online Journal